The effects of somatostatin on the release of tritiated dopamine (DA) formed continuously from tritiated tyrosine were studied in vitro in superfused striatal slices and in vivo in both caudate nuclei and both substantiae nigrae of halothane-anesthetized cats using a push-pull cannula technique. Somatostatin (3 X 10-l' to 3 X lop7 M) increased the spontaneous tritiated dopamine release from rat striatal slices. This effect was dose dependent and was completely prevented by tetrodotoxin (5 X lop7 M). When applied for 30 min in one cat caudate nucleus, somatostatin (10e7 M) immediately increased the local release of tritiated DA, while a gradual inhibition of the tritiated amine's efflux was observed in the contralateral caudate nucleus. No changes in tritiated dopamine were seen in either substantia nigra during or after the peptide's application in the caudate nucleus. These results suggest that somatostatin in the striatum may play a role in the local and the distal control of dopamine release from the terminals of dopaminergic nigrostriatal neurons.
Abstract
The effects of somatostatin on the release of tritiated dopamine (DA) formed continuously from tritiated tyrosine were studied in vitro in superfused striatal slices and in vivo in both caudate nuclei and both substantiae nigrae of halothane-anesthetized cats using a push-pull cannula technique. Somatostatin (3 X 10-l' to 3 X lop7 M) increased the spontaneous tritiated dopamine release from rat striatal slices. This effect was dose dependent and was completely prevented by tetrodotoxin (5 X lop7 M). When applied for 30 min in one cat caudate nucleus, somatostatin (10e7 M) immediately increased the local release of tritiated DA, while a gradual inhibition of the tritiated amine's efflux was observed in the contralateral caudate nucleus. No changes in tritiated dopamine were seen in either substantia nigra during or after the peptide's application in the caudate nucleus. These results suggest that somatostatin in the striatum may play a role in the local and the distal control of dopamine release from the terminals of dopaminergic nigrostriatal neurons.
Somatostatin, originally described as a hypothalamic neurohormone (see Reichlin, 1980) has been thought in the past few years to function as a neurotransmitter in the central nervous system. In fact, the uneven distribution of this peptide in the brain (Kobayashi et al., 1977) , its presence in nerve terminals (Epelbaum et al., 1977) , and its electrophysiological effects (see Reichlin, 1980 ) suggest that it may have a role in neurotransmission or neuromodulation.
Furthermore, somatostatin can be released from brain slices through a calcium-dependent mechanism (Lee and Iversen, 1981) and may act on specific receptors (Reubi et al., 1981; Srikant and Patel, 1981) which have been characterized in binding studies using radioactive analogues of the peptide. Such specific binding sites (Reubi et al., 1981; Srikant and Patel, 1981) as well as somatostatin-like immunoreactive neurons (Graybiel et al., 1981) turn. However, the function of somatostatin in this structure is totally unknown.
Numerous striatal neurotransmitters have been shown to modulate the release of dopamine (DA) from dopaminergic nigrostriatal neurons, a major afferent input to the striatum (see Giorguieff-Chesselet et al., 1980) . When injected intracerebroventricularly, somatostatin induced an increase in DA synthesis and turnover in several brain areas including the striatum (Garcia-Sevilla et al., 1978) . Therefore, one possibility may be that somatostatin plays a role in the local regulation of striatal dopaminergic transmission.
This hypothesis was investigated in the present study by measuring the effect of somatostatin on the release of tritiated dopamine ([3H]DA) newly synthesized from [3H]tyrosine.
Experiments were carried out both in vitro in rat striatal slices and in viva in the two caudate nuclei (CN) and substantiae nigrae of halothaneanesthetized cats, using a push-pull cannula technique. It will be shown that somatostatin applied in low concentration in the striatum not only locally increased [3H]DA release but also affected striatal efferents which modulate the activity of the contralateral nigrostriatal dopaminergic pathway.
Materials
and Methods
In vitro experiments
Striatal slices (0.3 mm thickness) of male SpragueDawley rats (200 to 500 gm) were prepared and superfused as described previously (Giorguieff et al., 1977) .
Briefly, slices from one striatum (50 mg of tissue) were put in microsuperfusion chambers (200 pl), maintained at 37°C and superfused at a rate of 2 ml/hr with an artificial oxygenated cerebrospinal fluid containing 50 pCi/ml of L-[3,5-"Hltyrosine (50 Ci/mmol). The r3H]tyrosine was purified, prior to the experiment, by high pressure liquid chromatography (Cheramy et al., 1981) . Superfusates were collected every 2.5 min on a protective solution (40 1.11 of thioglycolic acid, 10e3 M) on ice and stored at -2O'C, after addition of 2 ml of absolute ethanol, for no longer than 72 hr before the biochemical analysis.
In vivo experiments Cats of both sexes (2 to 3 kg) were anesthetized with halothane (3%), artificially ventilated through tracheotomy, monitored, and held stereotaxically as described previously (Cheramy et al., 1981) . One push-pull cannula was introduced in each CN and each substantia nigra according to the following coordinates: CN, A = 16, L = 4.5, H = 5; substantia nigra, A = 4, L = 3, H = -5. Each push-pull cannula was supplied continuously (300 pl/lO min) with an artificial cerebrospinal fluid containing 50 pCi/ml of ["Hltyrosine prepared as described above. Superfusates were collected in successive lo-min fractions in tubes containing an ice-cold stabilizing thioglycolic acid solution (lo-' M final concentration). Ethanol (1 ml) was added immediately to the collected fractions and samples were stored at -20°C until biochemical analysis was performed.
Histological controls
At the end of each experiment, the cat was perfused through the carotid artery with 10% formalin in isotonic saline under deep halothane anesthesia. Serial frontal sections of the brain were stained with cresyl violet and were submitted to histological control to determine the sites of superfusion.
Biochemical analysis
For both the in vitro and in vivo release studies, r3H] DA was separated from L-[3,5-"Hltyrosine, 3H-metabolites, and 3H-radiolysis compounds as described previously (Cheramy et al., 1981) . Briefly, samples were passed through an Amberlite and an alumina column, and r3H] DA present in the eluates was estimated by liquid scintillation spectrometry. Data were corrected for recovery (75%). The mean level of [3H]DA recovered in each fraction was 10 to 20 times the blank value which was identical to the counter background.
Data presentation and analysis 1. In vitro studies. In these experiments, drugs were added for either 7.5 or 17.5 min in the super-fusion medium, 25 min after the beginning of the super-fusion. Previously, we have shown (Giorguieff et al., 1977) that the spontaneous efflux of newly synthesized r3H]DA in continuously superfused striatal slices is calcium dependent, a characteristic of the physiological release of the transmitter. In control slices (no drugs added), it should be noted that the spontaneous release of [3H]DA after an initial 15-min labeling period slowly increased as a function of time. In each experiment, [3H]DA in each successive fraction was expressed as a percentage of an average spontaneous release calculated from the three fractions collected before the treatment. The changes in percentage of [3H]DA release during the drug treatments then were compared to [3H]DA release occurring in controls.
In the experiments with tetrodotoxin, the neurotoxin was added to the superfusion medium at the beginning of each trial. This treatment has been shown previously to reduce the spontaneous release of r3H]DA (Giorguieff et al., 1977 ). The application of somatostatin then was carried out in a similar fashion as described for the other experiments, and changes in [3H]DA release were compared to values obtained in slices superfused in the presence of tetrodotoxin alone.
2. In vivo studies. In each animal and for each cannula, [3H]DA in each successive fraction was expressed as a percentage of an average spontaneous release calculated from the five fractions collected before the application of somatostatin. The results obtained in treated animals are compared to control (untreated) animals.
In all cases, statistics were determined using the twotailed Student's t test with values of p < 0.05 considered significant.
Substances used
Somatostatin was synthesized and generously donated by Dr. Solange Lavielle, Paris, France. Tetrodotoxin crystalline was purchased from Sankyo Co., Ltd., Tokyo, Japan. L-[3,5-3H]tyrosine was purchased from New England Nuclear, Boston, MA, or Commissariat h L'Energie Atomique, Gif s/Yvette, France.
Results
Effect of somatostatin on the spontaneous release of fH]dopamine in vitro. In an initial study, a different concentration of somatostatin was added for 7.5 min to the superfusion medium of eight groups of striatal slices in the same experiment. Somatostatin in a concentration range from 3 X 10-l' to 3 x 10m7 M increased [3H]DA release above control values in a dose-dependent manner. This is shown in Figure 1 , which represents the mean value of ["HIDA released during three fractions of somatostatin's superfusion, expressed as a percentage of the mean value of [3H]DA release measured in the three fractions preceding the peptide's application. These effective concentrations of somatostatin correspond to the affinity of specific brain binding sites for this peptide (Reubi et al., 1981; Srikant and Patel, 1981) .
Further characterization of this effect was carried out by applying somatostatin, lo-' or lop7 M, for 15 min to rat striatal slices. The mean values of the results obtained in four or five experiments are reported in Figure 2 . At both concentrations, somatostatin significantly increased the ["HIDA release, this effect was slightly less pronounced with the lower concentration and, in both cases, lasted during the entire peptide's application.
Blockade of the somatostatin-enhanced rH]dopamine release in rat striatal slices in the presence of tetrodotoxin. Tetrodotoxin (5 x 10m7 M) was added to the superfusion medium throughout the entire experiment. This induces a decrease of approximately 50% of the [3H] ---_ 4 ------------ DA efflux, the reduction being unrelated to an inhibition of r3H]tyrosine uptake in striatal slices (Giorguieff et al., 1977) . Under these conditions, somatostatin (10m7 M) did not induce any significant changes in ["HIDA release when compared to slices continuously superfused with a medium containing the toxin (5 X 10m7 M) alone (Fig. 2) .
In vivo effect of somatostatin on pH]dopamine release in both caudate nuclei and substantiae nigrae in the cat. The spontaneous release of newly synthesized ["HIDA was measured in both CN and both substantiae nigrae of halothane-anesthetized cats, by means of pushpull cannulae. Somatostatin ( 10e7 M) added for 30 min to the superfusion medium of one CN induced an immediate, marked (250%) but short lasting (10 min) local increase of ["HIDA release. By contrast, in the contralatera1 CN, a progressive decrease of the 3H-amine outflow appeared during and after somatostatin's application. No significant changes in r3H]DA release were observed in the two substantiae nigrae (Fig. 3) .
Discussion
The present results reveal that somatostatin increases DA release when locally applied to rat striatal slices or in the cat CN. The dose-dependent increase in [3H]DA spontaneous release, induced in vitro by concentrations of somatostatin as low as 3 X lo-" M, suggests that this neuropeptide, which normally is present in the striatum (Kobayashi et al., 1977; Graybiel et al., 1981) , may contribute to a local regulation of the striatal dopaminergic transmission. However, due to the lack of specific blocker for somatostatin's receptors, it is presently impossible to further confirm the role of endogenous somatostatin in this regulatory process. Several other putative neurotransmitters or agonists of transmitter receptors have already been shown to affect newly synthetized [3H]DA release in the striatum (see Giorguieff-Chesselet et al., 1980 : Lubetzki et al., 1982 Reisine et al., 1982) . The actions of these compounds are blocked by specific receptor antagonists and can also be differentiated by their varying sensitivity to tetrodotoxin. In fact, whereas the effects of acetylcholine, glutamic acid (see GiorguieffChesselet et al., 1980) , D-Alaa-Met-enkephalinamide (Lubetzki et al., 1982) , and P-adrenergic agonists (Reisine et al., 1982) persist in the presence of tetrodotoxin, the enhancement of [3H]DA release induced by GABA (see Giorguieff-Chesselet et al., 1980) or by somatostatin was suppressed by this neurotoxin. The similarity between GABA's and somatostatin's effects is of potential importance since it has been shown in immunohistochemical studies of the nucleus reticular-is thalami (Oertel et al., 1981) that some brain neurons may contain both GABA and somatostatin. Because tetrodotoxin prevents action potentials, its blockade of somatostatin-induced C3H]DA release suggests that the peptide, instead of acting directly on dopaminergic nerve terminals, activates interneurons modulating dopaminergic transmission. However, a direct action of somatostatin on dopaminergic nerve terminals cannot be totally excluded since tetrodotoxin may have impaired the peptide's effect by inducing a change in the membrane potential of dopaminergic nerve terminals (see Giorguieff-Chesselet et al., 1980) . Application of somatostatin to the cat CN in uiuo induced an increase in local ["HIDA release which was more pronounced than its in vitro effect. This could be due either to a species difference in somatostatin's receptor sensitivity or to a dependence of somatostatin's action on the activity of nigrostriatal dopaminergic neurons. Interestingly, by contrast to other agents which also increase the "H-amine's release in the cat CN (see Giorguieff-Chesselet et al., 1980; Chesselet et al., 1981; Reisine et al., 1982) , somatostatin did not induce a second stimulation of ["HIDA outflow when removed from the superfusion medium. This clearly shows that the peptide interacts with dopaminergic neurons through mechanisms different from those of other striatal transmitters. Somatostatin's unique action is further supported by the effect induced in the contralateral CN. In fact, when similar experiments were performed with other transmitters or transmitter agonists (Chesselet et al., 1982; Reisine et al., 1982) which also locally increased [3H]DA efflux, no effect was observed in the contralateral structures examined. This suggests that changes in DA release in one CN are not the primary cause for alterations in the amine outflow in the contralateral CN. On the other hand, this contralateral effect cannot be due to the peptide's diffusion from the striatum since the volume of tissue superfused in our experimental conditions does not exceed about 4 mm3 around the tip of the cannula (Chesselet et al., 1982) . Therefore, the decrease of ["HIDA release in the contralateral CN is most probably related to an action of somatostatin on other striatal neurons or afferences in addition to the dopaminergic nerve endings.
This result brings new insights into the regulation of dopaminergic systems. The existence of a reciprocal relationship between the two nigrostriatal dopaminergic pathways has been demonstrated over the past few years (see Glowinski et al., 1980) . Changes in the activity of the contralateral dopaminergic neurons can be initiated by pharmacological manipulations in the substantia nigra and, in this case, the information's transfer seems to occur through the massa intermedia of the thalamus (Cheramy et al., 1981) . The in uiuo action of somatostatin reported in the present study shows that striatal efferents directly or indirectly affected by this peptide may also play a role in the regulation of contralateral striatal dopaminergic transmission. Whatever the anatomical support for somatostatin's distal effect on r3H]DA release might be, these data suggest that the neuropeptide could intervene in the physiological regulation of extrapyramidal systems which are known to play a role in sensorymotor integration (see Glowinski et al., 1980) . Furthermore, they extend previous findings showing that soma-
